lascco

New EU-funded HENIPROTECT project launches with LASCCO as partner to create first breathable treatment for Nipah virus

November 26, 2026.

LASCCO SA embarks on the EU-funded HENIPROTECT project together with 17 other leading partners across eight European countries to tackle one of the most concerning emerging infectious disease threats.

Supporting the European Union's priorities to strengthen health security and prepare for future pandemics, the Horizon-funded HENIPROTECT initiative was launched in September 2026 to develop a new, inhalable, neutralizing antibody therapy, against Nipah virus and related henipaviruses, including Hendra virus.

Listed among the World Health Organization (WHO) priority diseases of its R&D Blueprint, Nipah and Hendra viruses pose the greatest risk to global health, with mortality rates of up to 75 percent. There are currently no approved preventive treatments or therapies.

Over the next six years, HENIPROTECT aims to deliver a crucial treatment for Nipah virus and to establish a valuable blueprint for rapidly responding to future respiratory viral threats, in particular other viruses of the same Henipavirus genus, such as the highly pathogenic Hendra virus.

LASCCO will be responsible for the regulatory strategy and the non-clinical safety package of the project. It will also contribute to the preparation of the first-in-human trial and to the analysis and reporting of its results, and will lead the planning of the regulatory, manufacturing and market-access steps needed to bring the treatment to deployment.

About the HENIPROTECT project

Title: HENIPROTECT – Inhalable antibody therapy targeting henipaviruses
Timeline: 2026–2031
Total budget: EUR 16.3 million
Coordinator: INSERM, France
Partners: 18 organizations from 8 countries

About LASCCO

LASCCO SA is a biomedical-technology company based at the Biopôle of Lausanne, Switzerland. The primary objective of LASCCO is to develop promising discovery-stage therapeutics and diagnostics stemming from research institute labs up to advanced clinical stage. LASCCO has developed in-depth expertise in the fields of critical care and emergency medicine, and its portfolio is currently composed of innovative products aiming at fighting sepsis and treating severe bacterial and viral infections.

Follow us on LinkedIn (LASCCO) or visit our website www.lascco.com.

Financial statement

Funded by the European Union (Grant Agreement 101286662). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.

Contact:

Frédéric Lajaunias

info@lascco.com